Amneal reports positive Phase 4 data for CREXONT in Parkinson’s treatment
Amneal Pharmaceuticals (NASDAQ:AMRX) has announced encouraging interim data from the Phase 4 ELEVATE-PD clinical trial, which evaluates the efficacy and safety of CREXONT (carbidopa and levodopa) extended-release capsules in patients living with Parkinson’s disease.










